Skip to content

Controlled-Release Oxycodone Versus Naproxen at Home After Ambulatory Surgery: A Randomized Controlled Trial

Controlled-Release Oxycodone Versus Naproxen at Home After Ambulatory Surgery: A Randomized Controlled Trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02152592
Enrollment
105
Registered
2014-06-02
Start date
2007-10-31
Completion date
Unknown
Last updated
2014-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain After Ambulatory Surgery

Keywords

Postoperative pain, Ambulatory surgery, NSAIDS, CR Oxycodone, Compliance to study medication

Brief summary

the primary objective of this study is to assess and compare the efficacy, safety and benefits of Controlled Release (CR) oxycodone/paracetamol with our current pain protocol (paracetamol/naproxen) in the treatment of acute postoperative pain at home after painful day-case surgery. We hypothesize that ambulatory patients postoperatively treated with oxycodone/paracetamol will achieve better pain relief with equal side effects compared to patients treated with paracetamol/naproxen. Our second goal is to assess analgesic adherence in the outpatient setting. Endpoints: Primary endpoints: pain intensity (Visual analogue scale) Secondary endpoints: - side-effects/ adverse effects of study medication * patient satisfaction with pain treatment * compliance to study medication Study design: Patients scheduled for painful ambulatory surgery (knee arthroscopy, unilateral open or laparoscopic inguinal hernia repair) will be enrolled in an open randomized controlled trial (RCT) at our pre-assessment clinic. Subjects will be enrolled by a study nurse and will be randomized into one of three study treatment groups using a computer-generated list. Patients in group 1 (PCM/NAPR) are assigned to postoperative analgesia using naproxen 500 mg orally twice a day for 48 hours postoperatively. Patients assigned to group 2 (PCM/Oxy1) receive CR oxycodone 10 mg orally twice a day for 24 hours. Patients in group 3 (PCM/Oxy2) are postoperatively treated witch CR oxycodone 10 mg orally twice a day for 48 hours. All patients also receive paracetamol 1000 mg orally four times a day for 48 hours postoperatively. Recovery after discharge will be assessed using a diary for up to 48 hours after surgery. Three times a day, patients have to rate pain at rest and movement (VAS), fatigue, nausea, vomiting, pruritus, miction problems, pyrosis, and abdominal complaints. Furthermore, compliance to the use of the study medication will be assessed by checking whether the patients took the study medication as prescribed and if any other pain medication was used. Compliance will be assessed three times a day and patients will be divided into three groups according to medication use: always = full compliance, sometimes = partial compliance, or never = no compliance. Finally, overall satisfaction with the postoperative pain treatment will be assessed (score 0-10).

Interventions

DRUGPCM/Oxy1

Controlled Release oxycodone 10 mg orally twice a day for 24 hours

DRUGPCM/Oxy2

CR oxycodone 10 mg orally twice a day for 48 hours

Sponsors

Maastricht University Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Patients scheduled for painful ambulatory surgery (knee arthroscopy, unilateral open or laparoscopic inguinal hernia repair) * American Society of Anesthesiologists (ASA) physical classification I or II

Exclusion criteria

* cognitive impairment, * preoperative pharmacologic pain treatment * allergy to or a contraindication for taking the study medication (e.g. paracetamol, oxycodone, naproxen or another NSAID) * porphyria * pregnancy or lactation * history of severe renal, hepatic, pulmonary, or cardiac failure * current symptoms or history of gastrointestinal bleeding, ileus or chronic obstipation * history of substance abuse, or use of medication with a suppressive effect on the central nervous system

Design outcomes

Primary

MeasureTime frameDescription
a difference on a pain visual analogue scale between study groupsup to 48 hoursa difference of 15mm or more on a visual analogue scale between three study groups is considered clinically relevant

Secondary

MeasureTime frame
Incidence of adverse effects of study medicationup to 48 hours

Other

MeasureTime frame
Adherence to study medicationup to 48 hours

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 19, 2026